Mealey's (March 30, 2023, 4:03 PM EDT) -- WASHINGTON, D.C. — In a March 29 amicus curiae brief filed at the U.S. Supreme Court’s request, the U.S. government recommended that the high court grant a petition for certiorari in which Teva Pharmaceuticals USA Inc. seeks clarification about when a generic drug maker may be found liable for patent infringement when it has followed statutory deadlines requiring the omission from labeling of any still-patented uses for a drug....